中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (6): 1776-1788.doi: 10.4103/NRR.NRR-D-23-01051

• 原著:退行性病与再生 • 上一篇    下一篇

硫化氢可减轻亨廷顿病的氧化应激

  

  • 出版日期:2025-06-15 发布日期:2024-11-12

Hydrogen sulfide reduces oxidative stress in Huntington’s disease via Nrf2

Zige Jiang1, #, Dexiang Liu2, #, Tingting Li1 , Chengcheng Gai1 , Danqing Xin1 , Yijing Zhao1 , Yan Song1 , Yahong Cheng1 , Tong Li3, *, Zhen Wang1, *   

  1. 1 Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China;  2 Department of Medical Psychology and Ethics, School of Basic Medicine Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China;  3 Department of Neurosurgery Surgery, Qingdao Municipal Hospital, Qingdao, Shandong Province, China
  • Online:2025-06-15 Published:2024-11-12
  • Contact: Zhen Wang, PhD, wangzhen@sdu.edu.cn; Tong Li, PhD, kiddlitong@163.com.
  • Supported by:
    This study was supported by the National Natural Science Foundation of China, Nos. 82271327 (to ZW), 82072535 (to ZW), 81873768 (to ZW), and 82001253 (to TL).

摘要:

亨廷顿病的病理生理学改变与较高水平的神经毒素喹啉酸有关。喹啉酸的积累会导致氧化应激,从而引起神经毒性。然而,喹啉酸在亨廷顿病病理生理学中的分子和细胞机制尚不清楚。实验给予小鼠纹状体和PC12细胞喹啉酸干预以模拟亨廷顿病,可见小鼠血清和PC12细胞内的硫化氢水平下降,且硫化氢生成酶胱硫氨酸β-合成酶水平下调。而以硫化氢供体NaHS模拟内源性硫化氢增加可促进血清和神经元中硫化氢水平以及纹状体和神经元中胱硫氨酸β-合成酶的表达,同时改善了喹啉酸所致纹状体和PC12细胞中的氧化失衡和线粒体功能障碍。硫化氢的这些有益作用与Nrf2表达的上调密切相关。而后以ML385抑制Nrf2的表达,则可逆转硫化氢对喹啉酸诱导的氧化应激的有益影响。综上,硫化氢可通过激活Nrf2减轻亨廷顿病的氧化应激,成为亨廷顿病的新型神经保护候选药物。

https://orcid.org/0000-0003-3173-6961 (Zhen Wang); https://orcid.org/0000-0002-2608-2855 (Tong Li)

关键词:

喹啉酸, 硫化氢, 胱硫氨酸β-合成酶, 氧化应激, Nrf2, 活性氧, 亨廷顿病, 线粒体, 细胞凋亡, 神经可塑性

Abstract: The pathophysiology of Huntington’s disease involves high levels of the neurotoxin quinolinic acid. Quinolinic acid accumulation results in oxidative stress, which leads to neurotoxicity. However, the molecular and cellular mechanisms by which quinolinic acid contributes to Huntington’s disease pathology remain unknown. In this study, we established in vitro and in vivo models of Huntington’s disease by administering quinolinic acid to the PC12 neuronal cell line and the striatum of mice, respectively. We observed a decrease in the levels of hydrogen sulfide in both PC12 cells and mouse serum, which was accompanied by down-regulation of cystathionine β-synthase, an enzyme responsible for hydrogen sulfide production. However, treatment with NaHS (a hydrogen sulfide donor) increased hydrogen sulfide levels in the neurons and in mouse serum, as well as cystathionine β-synthase expression in the neurons and the mouse striatum, while also improving oxidative imbalance and mitochondrial dysfunction in PC12 cells and the mouse striatum. These beneficial effects correlated with upregulation of nuclear factor erythroid 2-related factor 2 expression. Finally, treatment with the nuclear factor erythroid 2-related factor 2 inhibitor ML385 reversed the beneficial impact of exogenous hydrogen sulfide on quinolinic acid-induced oxidative stress. Taken together, our findings show that hydrogen sulfide reduces oxidative stress in Huntington’s disease by activating nuclear factor erythroid 2-related factor 2, suggesting that hydrogen sulfide is a novel neuroprotective drug candidate for treating patients with Huntington’s disease. 

Key words: apoptosis, cystathionine-β-synthase, nuclear factor erythroid 2-related factor 2, Huntington’s disease, hydrogen sulfide, mitochondrion, neuroplasticity, oxidative stress, quinolinic acid, reactive oxygen species